Search research articles
Contact Us
Filters
Showing results (1-10 of 8) with videos related to
Page
of 1
Sort By:
Revista Brasileira De Hematologia E Hemoterapia
|
May 22, 2016
Bilateral breast plasmacytoma: a clinical case report
Thais Rodrigues da Cunha Fischer, Fabiana Higashi, Edvan de Queiroz Crusoe, et al.
Hematology, Transfusion and Cell Therapy
|
March 10, 2018
Multiple myeloma and central nervous system involvement: experience of a Brazilian center
Ana Luiza Miranda Silva Dias, Fabiana Higashi, Ana Lúcia M Peres, et al.
Hematology, Transfusion and Cell Therapy
|
September 16, 2022
Impact of the lactate dehydrogenase in association with the International Staging System prognostic score in multiple myeloma patients treated in real life
Maricy Almeida Viol Ferreira Lopes, Fabiana Higashi, Edvan de Queiroz Crusoe, et al.
Revista Brasileira De Hematologia E Hemoterapia
|
November 20, 2016
Is it feasible to use granulocyte-colony stimulating factor alone to mobilize progenitor cells in multiple myeloma patients induced with a cyclophosphamide, thalidomide and dexamethasone regimen?
Edvan de Queiroz Crusoe, Fabiana Higashi, Gracia Aparecida Martinez, et al.
Hematology, Transfusion and Cell Therapy
|
September 15, 2019
Effect of thalidomide on bone marrow angiogenesis in multiple myeloma patients
Priscilla Cury de Camargo Cury, Fabiana Higashi, Flávia Fernandes Silva Zacchi, et al.
Revista Brasileira De Hematologia E Hemoterapia
|
March 14, 2014
Outcomes of autologous transplantation for multiple myeloma according to different induction regimens
Edvan de Queiroz Crusoe, Fabiana Higashi, Maria Paula Nalesso Camargo Padilha, et al.
Revista Brasileira De Hematologia E Hemoterapia
|
July 18, 2014
[Not Available]
Edvan de Queiroz Crusoe, Fabiana Higashi, Maria Paula Nalesso Camargo Padilha, et al.
Hematology, Transfusion and Cell Therapy
|
September 21, 2019
Superiority of the triple combination of bortezomib, cyclophosphamide and dexamethasone versus cyclophosphamide, thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma, eligible for transplantation
Edvan De Queiroz Crusoe, Fabiana Higashi, Gracia Martinez, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 8) with videos related to
Sort By:
Page
of 1
Revista Brasileira De Hematologia E Hemoterapia
|
May 22, 2016
Bilateral breast plasmacytoma: a clinical case report
Thais Rodrigues da Cunha Fischer, Fabiana Higashi, Edvan de Queiroz Crusoe, et al.
Hematology, Transfusion and Cell Therapy
|
March 10, 2018
Multiple myeloma and central nervous system involvement: experience of a Brazilian center
Ana Luiza Miranda Silva Dias, Fabiana Higashi, Ana Lúcia M Peres, et al.
Hematology, Transfusion and Cell Therapy
|
September 16, 2022
Impact of the lactate dehydrogenase in association with the International Staging System prognostic score in multiple myeloma patients treated in real life
Maricy Almeida Viol Ferreira Lopes, Fabiana Higashi, Edvan de Queiroz Crusoe, et al.
Revista Brasileira De Hematologia E Hemoterapia
|
November 20, 2016
Is it feasible to use granulocyte-colony stimulating factor alone to mobilize progenitor cells in multiple myeloma patients induced with a cyclophosphamide, thalidomide and dexamethasone regimen?
Edvan de Queiroz Crusoe, Fabiana Higashi, Gracia Aparecida Martinez, et al.
Hematology, Transfusion and Cell Therapy
|
September 15, 2019
Effect of thalidomide on bone marrow angiogenesis in multiple myeloma patients
Priscilla Cury de Camargo Cury, Fabiana Higashi, Flávia Fernandes Silva Zacchi, et al.
Revista Brasileira De Hematologia E Hemoterapia
|
March 14, 2014
Outcomes of autologous transplantation for multiple myeloma according to different induction regimens
Edvan de Queiroz Crusoe, Fabiana Higashi, Maria Paula Nalesso Camargo Padilha, et al.
Revista Brasileira De Hematologia E Hemoterapia
|
July 18, 2014
[Not Available]
Edvan de Queiroz Crusoe, Fabiana Higashi, Maria Paula Nalesso Camargo Padilha, et al.
Hematology, Transfusion and Cell Therapy
|
September 21, 2019
Superiority of the triple combination of bortezomib, cyclophosphamide and dexamethasone versus cyclophosphamide, thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma, eligible for transplantation
Edvan De Queiroz Crusoe, Fabiana Higashi, Gracia Martinez, et al.
Page
of 1